MARKET

AMGN

AMGN

Amgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

251.96
+1.65
+0.66%
Opening 15:40 05/14 EDT
OPEN
253.28
PREV CLOSE
250.31
HIGH
254.59
LOW
251.16
VOLUME
1.49M
TURNOVER
--
52 WEEK HIGH
276.69
52 WEEK LOW
210.28
MARKET CAP
144.76B
P/E (TTM)
20.87
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 7h ago
Amgen Inc. stock rises Thursday, still underperforms market
Shares of Amgen Inc. inched 0.49% higher to $252.07 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...
marketwatch.com · 23h ago
Insights on the Recombinant DNA Technology Global Market to 2027 - Featuring Amgen, Bamboo Therapeutics and Biocon Among Others
, /PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 23h ago
Swaine & Leidel Wealth Services, LLC Buys AvalonBay Communities Inc, Nasdaq Inc, iShares ...
GuruFocus News · 1d ago
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
Zacks · 1d ago
New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
, /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal NAVIGATOR Phase 3 trial demonstrating superiority across every primary and key secondary endpoin...
PR Newswire - PRF · 1d ago
Universal PropTech Confirms Launch of ISBRG Corp's SpotLight-19(C) Clinical Trial and New R&D Funding Assistance
Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - Universal PropTech Inc. (TSXV: UPI) (OTCQB: UPIPF) (FSE: 8LH) ("" or the "") is pleased to announce that ISBRG Corp., in which UPI owns a minority interest (see press release dated February 18, 2021), ann...
Newsfile Corp · 1d ago
Grimes & Company, Inc. Buys Costco Wholesale Corp, PerkinElmer Inc, Consumer Discretionary ...
GuruFocus News · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMGN. Analyze the recent business situations of Amgen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 30 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMGN stock price target is 255.42 with a high estimate of 298.00 and a low estimate of 185.00.
EPS
Institutional Holdings
Institutions: 2.75K
Institutional Holdings: 464.07M
% Owned: 80.77%
Shares Outstanding: 574.55M
TypeInstitutionsShares
Increased
882
12.31M
New
238
3.07M
Decreased
756
21.21M
Sold Out
128
1.47M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.52%
Pharmaceuticals & Medical Research
+1.23%
Key Executives
Chairman/Chief Executive Officer/President/Director
Robert Bradway
Chief Financial Officer/Executive Vice President
Peter Griffith
Executive Vice President/General Counsel/Secretary
Jonathan Graham
Executive Vice President/Director of Human Resources
Lori Johnston
Executive Vice President
Murdo Gordon
Executive Vice President
David Reese
Executive Vice President
Esteban Santos
Senior Vice President
David Piacquad
Lead Director/Independent Director
Robert Eckert
Independent Director
Wanda Austin
Chief Accounting Officer/Vice President - Finance
Linda Louie
Independent Director
Brian Druker
Independent Director
Gregory Garland
Independent Director
Fred Hassan
Independent Director
Charles Holley
Independent Director
Tyler Jacks
Independent Director
Ellen Kullman
Independent Director
Amy Miles
Independent Director
Ronald Sugar
Independent Director
Robert Williams
Independent Director
R. Sanders Williams
Declaration Date
Dividend Per Share
Ex-Div Date
03/03/2021
Dividend USD 1.76
05/14/2021
12/16/2020
Dividend USD 1.76
02/11/2021
10/21/2020
Dividend USD 1.6
11/13/2020
07/23/2020
Dividend USD 1.6
08/14/2020
03/04/2020
Dividend USD 1.6
05/15/2020
12/11/2019
Dividend USD 1.6
02/13/2020
10/22/2019
Dividend USD 1.45
11/14/2019
08/02/2019
Dividend USD 1.45
08/14/2019
03/07/2019
Dividend USD 1.45
05/16/2019
12/07/2018
Dividend USD 1.45
02/14/2019
10/23/2018
Dividend USD 1.32
11/15/2018
07/31/2018
Dividend USD 1.32
08/16/2018
03/07/2018
Dividend USD 1.32
05/16/2018
12/12/2017
Dividend USD 1.32
02/14/2018
10/24/2017
Dividend USD 1.15
11/16/2017
07/28/2017
Dividend USD 1.15
08/15/2017
03/07/2017
Dividend USD 1.15
05/15/2017
12/20/2016
Dividend USD 1.15
02/13/2017
10/14/2016
Dividend USD 1
11/14/2016
07/22/2016
Dividend USD 1
08/15/2016
03/02/2016
Dividend USD 1
05/13/2016
12/15/2015
Dividend USD 1
02/11/2016
10/14/2015
Dividend USD 0.79
11/12/2015
07/28/2015
Dividend USD 0.79
08/13/2015
03/04/2015
Dividend USD 0.79
05/12/2015
12/17/2014
Dividend USD 0.79
02/10/2015
10/17/2014
Dividend USD 0.61
11/10/2014
07/25/2014
Dividend USD 0.61
08/12/2014
03/05/2014
Dividend USD 0.61
05/13/2014
12/13/2013
Dividend USD 0.61
02/11/2014
10/16/2013
Dividend USD 0.47
11/12/2013
07/26/2013
Dividend USD 0.47
08/14/2013
03/06/2013
Dividend USD 0.47
05/14/2013
12/13/2012
Dividend USD 0.47
02/11/2013
10/10/2012
Dividend USD 0.36
11/13/2012
07/19/2012
Dividend USD 0.36
08/14/2012
03/15/2012
Dividend USD 0.36
05/14/2012
12/15/2011
Dividend USD 0.36
02/13/2012
10/13/2011
Dividend USD 0.28
11/15/2011
07/28/2011
Dividend USD 0.28
08/16/2011
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.